Effector T cell and alloreactive T cell

Effector T cells and alloreactive T cells are specialized populations of lymphocytes that serve as the primary mediators of adaptive immunity and the principal drivers of transplant rejection and graft-versus-host disease (GVHD) [1], [3]. Effector T cells are activated lymphocytes that have differentiated to execute specific immune functions, such as the secretion of pro-inflammatory cytokines or the direct lysis of target cells [10], [14]. Alloreactive T cells are a subset characterized by their ability to recognize and respond to foreign major histocompatibility complex (MHC) molecules, leading to an immune attack against allogeneic tissues [5], [7]. These cell populations are the primary targets of immunosuppressive therapies designed to prevent or treat organ rejection and GVHD [3], [11]. Pharmacological agents targeting these cells include calcineurin inhibitors (e.g., cyclosporine), mTOR inhibitors (e.g., sirolimus), and monoclonal antibodies directed against surface receptors like CD3, CD25, and CD2 [3], [13]. While these therapies are critical for graft survival, they often cause broad immunosuppression, which significantly increases the risk of opportunistic infections and the development of malignancies such as post-transplant lymphoproliferative disorder [3], [12].

Other names

Activated T cellAllospecific T cellCytotoxic T lymphocyteHelper T cellMemory effector T cellT-effector cell

Inhibition of calcineurin signaling, blockade of the mammalian target of rapamycin (mTOR) pathway, antagonism of the interleukin-2 receptor (CD25), blockade of T-cell costimulation (CD80/86-CD28 interaction), and direct depletion of T-cell populations via targeting of surface markers such as CD3, CD2, or CD52.